David Davidson

Biography

  David Davidson has served as our Chief Scientific Officer since November 2013. From May 2012 to October 2013, David led the Research and Development activities on our Point of Care project, leading to the launch of a rapid, simple-to-use skin-care genetic test with our partners, Geneonyx. David has more than 15 years of industry experience working in positions of increasing responsibility in biotechnology, drug discovery and diagnostics businesses. Previously, David served at SPD Development Company, a consumer diagnostics business headquartered in Geneva, Switzerland, which is a joint venture between Alere and Procter & Gamble, and prior to that at Millipore (previously known as Serologicals and Upstate Ltd before acquisition by Millipore) in their Drug Discovery Business Unit, and PPL Therapeutics plc, the transgenic technology company most noted for Dolly the Sheep. David received a B.Sc. in Immunology from the University of Glasgow and carried out post-graduate research in peptide vaccines and therapeutics prior to joining industry.

Research Interest

 Immunology, Pharmaceutical